Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
Looks to enable patients all over the world to have equal access to the highest quality of cancer care and research
Cancer is one of the most democratic illnesses out there — it does not care who you are, what you look like, or where you’re from; however, the clinical trial system is anything but democratic. Less than 8% of eligible cancer patients participate in clinical studies, which drastically limits our understanding of the disease and the ways in which it affects a diverse range of populations. Pi Health’s platform rapidly increases patient enrollment around the globe by integrating software into a growing international network of clinical trial sites across four continents to empower life sciences companies to develop medicines. This not only reaches a more diverse patient population, faster, but it also significantly reduces provider friction and biopharma costs through the process.
“We’ve created an entirely new infrastructure for the clinical trial process, which has become mired in inefficiencies that impede progress,” said co-founder and CEO
While hundreds of SaaS solutions have entered the market, none are comprehensive. As a result, the system’s infrastructure has devolved into a sea of point-solutions with unnecessary software silos and convoluted workflows. Furthermore, none were built to seamlessly collect the type and quality of data the FDA requires companies to submit to get their drugs approved.
“Today’s clinical trials infrastructure is a maze of Excel spreadsheets, paper binders and manual data entry into various point-solutions. Many companies have tried to solve this clinical trials conundrum. None has taken the bold, comprehensive and global approach that
Furthermore, the software has the potential to dramatically mitigate administrative burdens and speed up clinical trial processes, through its implementation of generative AI in features such as automation of clinical documentation, patient matching, data transformations and adverse event monitoring. The team has ensured this technology is relevant, resonant, and usable across the globe, as anything less would continue to maintain an undemocratic status quo for a democratic disease.
“With Pi Health's AI-driven platform, we believe that the entire clinical trial system will be revolutionized for the better,” said
The Series A funding will support expansion of
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313127151/en/
For more information, please contact press@pihealth.ai or 646.727.60093
Source: